In the first study focusing on patients with BM from non-small cell lung cancer (NSCLC) and assessing the effects of immunotherapy, Goldberg SB (13) reported that 29.7% of PD-L1-positive patients responded to treatment of BM. Here, CD274 is linked to non-small cell lung carcinoma.